Atria Investments Inc Grows Stake in AstraZeneca PLC (NASDAQ:AZN)

Atria Investments Inc boosted its stake in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 20.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 124,501 shares of the company's stock after purchasing an additional 20,813 shares during the period. Atria Investments Inc's holdings in AstraZeneca were worth $9,151,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. One Wealth Advisors LLC bought a new position in shares of AstraZeneca during the first quarter worth about $260,000. Journey Strategic Wealth LLC increased its position in shares of AstraZeneca by 28.5% during the first quarter. Journey Strategic Wealth LLC now owns 9,061 shares of the company's stock worth $666,000 after acquiring an additional 2,008 shares in the last quarter. Advisor OS LLC bought a new stake in AstraZeneca during the first quarter worth $213,000. Kovack Advisors Inc. bought a new stake in AstraZeneca in the 1st quarter worth about $213,000. Finally, SFE Investment Counsel bought a new position in AstraZeneca during the first quarter valued at about $523,000. 20.35% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

AZN has been the topic of several recent research reports. BNP Paribas started coverage on AstraZeneca in a research report on Tuesday, April 15th. They set an "outperform" rating and a $75.00 target price on the stock. Berenberg Bank set a $97.00 price objective on AstraZeneca in a research note on Wednesday, July 9th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $89.00.

AstraZeneca Stock Down 1.4%

AstraZeneca stock traded down $1.02 on Friday, hitting $72.66. 6,200,753 shares of the stock traded hands, compared to its average volume of 3,846,153. AstraZeneca PLC has a 1 year low of $61.24 and a 1 year high of $87.68. The company has a current ratio of 0.90, a quick ratio of 0.70 and a debt-to-equity ratio of 0.65. The firm has a market cap of $225.34 billion, a P/E ratio of 29.18, a price-to-earnings-growth ratio of 1.35 and a beta of 0.37. The business's fifty day simple moving average is $71.15 and its 200 day simple moving average is $71.11.

AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its earnings results on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, topping analysts' consensus estimates of $1.10 by $0.14. AstraZeneca had a return on equity of 33.14% and a net margin of 14.14%. The business had revenue of $13.59 billion during the quarter, compared to analyst estimates of $13.71 billion. During the same quarter last year, the company earned $2.06 EPS. The company's quarterly revenue was up 7.2% compared to the same quarter last year. As a group, sell-side analysts forecast that AstraZeneca PLC will post 4.51 earnings per share for the current year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.